Monday, 20 May 2019

You are here

Lupus Microbiome May Drive Disease Activity

Silverman and colleagues have published their study of the fecal microbiome of systemic lupus erythematosus (SLE) patients and found roughly five times more gut bacteria known as Ruminococcus gnavus, and that these abnormalities in microbiota can correlate with measures of disease severity in SLE.

They studied 61 women diagnosed with SLE and 17 age-matched controls without lupus. They assessed microbiota for candidate pathobionts using fecal 16 S rRNA analyses along with sera profiled for antibacterial and autoantibody responses, and clinical activity measures. 

The found an overall 5-fold greater representation of Ruminococcus gnavus (RG) of the Lachnospiraceae family.

Notably, disease "flares" correlated with major increases in R. gnavus bacterial growth in the gut, as anti-RG antibodies correlated directly with SLEDAI score and anti-native DNA levels, and inversely with C3 and C4 levels.

Highest levels of serum anti-RG strain-restricted antibodies were detected in those with active nephritis (including Class III and IV) in the discovery cohort, with findings validated in two independent cohorts.

These findings suggest a specific strain of a gut commensals may contribute to the immune pathogenesis of lupus nephritis.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Risk Score Predicts Thrombosis Recurrence in APS

A combination risk score helped predict recurrent thrombosis -- particularly arterial -- among patients with antiphospholipid syndrome (APS), an international study found.

Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus

A Morbidity and Mortality Weekly Report on a registry of systemic lupus erythematosus (SLE) patients from two Georgia counties (Fulton and Dekalb) shows SLE mortality was 2-3 times higher compared to the general population, especially amongst blacks; notably deaths occurred sooner after diagnosis and at a mean age approximately 13 years younger.

Calcineurin Inhibitors in Anti-Synthetase Dermatomyositis ILD

A pilot treatment study of patients with anti-aminoacyl-tRNA synthetase antibody–positive polymyositis/dermatomyositis-associated interstitial lung disease (anti-ARS-PM/DM-ILD) shows therapy with glucocorticoids and calcineurin inhibitors (CNI) to be highly effective. 

Biomarkers Predict Thrombosis in Lupus

A composite risk score that included three biomarkers predicted thrombotic events among patients with systemic lupus erythematosus (SLE), a cross-sectional study found.

Monocyte Patrolling Contributes to Lupus Glomerulonephritis

Systemic lupus erythematosus (SLE) is an autoimmune disease with a propensity to develop glomerulonephritis (47-70%) or end-stage kidney disease despite therapy.

Hallmarks of the disease are the appearance of immune complexes (IC) containing autoreactive Abs and TLR-activating nucleic acids, whose deposition in kidney glomeruli is suspected to promote tissue injury and glomerulonephritis (GN).